Impaired striatal XXXX receptor development: differential D-1 regulation in adults.

@entity10095 @entity935 @entity11054 @entity1767 @entity35
Previous reports have indicated that prenatal, but not postnatal, @entity1767 impairs the ontogenic development of striatal @entity935 D-2 receptors. In the present study a specific D-2 receptor antagonist, @entity11054 (1.0 mg/kg i.p.) and/or a specific D-1 receptor antagonist, @entity10095 (0.30 mg/kg i.p.), was administered to @entity35 for 32 successive days from birth. Postnatal @entity11054 and @entity10095 treatments markedly impaired the development of striatal @entity935 D-2 and D-1 receptors, respectively, at 12 weeks after birth. @entity11054 did not affect D-1 receptor development and did not modify the effect of @entity10095 treatment. Also, @entity10095 did not affect D-2 receptor development and did not modify the effect of @entity11054 treatment. When @entity35 with impaired development of striatal D-2 receptors were challenged at 12 weeks with @entity11054 (1.0 mg/kg per day i.p. x 17 days) D-2 receptors did not up-regulate. However, when @entity35 with impaired development of striatal D-1 receptors were challenged at 12 weeks with @entity10095 (0.30 mg/kg per day i.p. x 17 days) D-1 receptors did up-regulate. These findings demonstrate that postnatal treatment with D-1 and D-2 receptor antagonists can permanently impair the development of striatal D-1 and D-2 receptors. Moreover, the ability of developmentally impaired striatal D-1 receptors to up-regulate in adulthood appears to be greater than that for the developmentally impaired striatal D-2 receptors.
